SRR8942967
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.620
- INTERFERON_GAMMA_RESPONSE+0.380
- TGF_BETA_SIGNALING+0.290
- MYOGENESIS+0.280
- UV_RESPONSE_DN+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.210
- APICAL_JUNCTION+0.200
- APICAL_SURFACE+0.200
- HEDGEHOG_SIGNALING+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
Top 10 suppressed
- SPERMATOGENESIS-0.350
- E2F_TARGETS-0.330
- MYC_TARGETS_V1-0.300
- PROTEIN_SECRETION-0.300
- PANCREAS_BETA_CELLS-0.290
- INFLAMMATORY_RESPONSE-0.270
- KRAS_SIGNALING_UP-0.240
- G2M_CHECKPOINT-0.220
- ALLOGRAFT_REJECTION-0.160
- TNFA_SIGNALING_VIA_NFKB-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R75 | — | — | 0.805 |
| 2 | SRR8943013 | — | — | 0.696 |
| 3 | 49718_S125 | — | cohortA1 | 0.695 |
| 4 | SRR8518122 | — | C | 0.675 |
| 5 | MNG695 | — | — | 0.674 |
| 6 | MDT-AP-0601 | Med | Medulloblastoma | 0.643 |
| 7 | MDT-AP-0595 | Med | Medulloblastoma | 0.637 |
| 8 | BS_HSHN8PBB | low-grade glioma | — | 0.634 |
| 9 | EPT0521 | EPN | Posterior Fossa EPN | 0.628 |
| 10 | MNG1254 | — | — | 0.626 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.620 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |